Pharma/Regulatory

Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Eli Lilly and company. All coverage content is independently selected by RheumNow and its faculty.
Adela Castro Tweet
@AdelaCastro222
CAR-T in SLE 2026 -Autologous CART: likely to achieve target faster (shorter time for SLEDAI/DORIS) -CD19-vs dual target (BCMA): no significant difference on SLEDAI -Pt w/ LN at baseline had steeper decline on SLEDAI -SAFETY: 64% of pts had CRS manageable (low grade) 95% of https://t.co/XyMOeoSpPL
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Eric Dein Tweet
@ericdeinmd
Yr in Rvw #ACR26 Sotatercept in PAH, activin-signaling inhib. Decr excess prolif PA smooth musc cells NEJM 2025 Stopped early 2/2 equipoise 77% less risk of clinical wors, +40 wk event-fr surv, 70% more likely to impr WHO fxnal class Watch: polycythemia, pericardial eff @RheumNow https://t.co/prV8L5QnWQ
Article

3 x IL-23 = IL do Better (11.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA. 

Article

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab  (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor

Article

Mixed Drinks, Mixed Results (10.30.2026)

Jack Cush, MD

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis

Peter Nash Tweet
@drpnash
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy APLAR Seoul 2026 #CAR-T #Rheum Now
Dr. John Cush Tweet
@RheumNow
2024 web survey of German rheumatologists on CAR-T & T-cell redirecting therapies. 95% willing to refer pts to specialized centers; but 5% (most severe) are suitable for TCRT. Barriers cited: high costs (82%), limited experience (65%) & limited # appropriate Pts (35%). 4.86/10 https://t.co/o62uRVsIC7
Article

The Efficacy of Ianalumab in Sjögren’s Disease

Jack Cush, MD

The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.

Topic Videos
×